Non-Inferiority Studies May (Bio)Creep Out Of Limelight After GAO Report
Executive Summary
A report on FDA's use of non-inferiority trials by the Government Accountability Office could in fact signal the end of the political wrangling over the study method
You may also be interested in...
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials